WebNews
Please enter a web search for web results.
NewsWeb
One-dose gene therapy shows up to 62% cut in bad cholesterol in early trial
8+ hour, 11+ min ago (493+ words) A Phase 1b clinical trial of Eli Lilly's gene therapy VERVE-102 has shown up to 62% reduction in LDL cholesterol with a single dose, raising hopes for long-term treatment of hypercholesterolaemia and heart disease risk. A one-time gene therapy for treating hypercholesterolaemia…...
Gene-editing cholesterol away, new Alzheimer's findings and a supplement warning
1+ day, 3+ hour ago (383+ words) A single infusion. A dramatic drop in bad cholesterol. And results that may last a lifetime. An experimental gene-editing treatment is turning heads in the medical world " and researchers say it could one day change the way heart'disease is prevented…...
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
6+ day, 6+ hour ago (197+ words) " "Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)" " " "CR rate now 95% (19 of 20 patients)" " " All CRs reached within 1 year of follow-up post-dosing" " " No relapses to-date observed for patients who have reached CR" " " All subsequently enrolled patients…...
PREMIA and Lind Form Lind Asia to Expand AI-Powered Clinical Trial Screening Across Asia-Pacific
6+ hour, 6+ min ago (278+ words) TAIPEI and SAN MATEO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Precision Medicine Asia, Limited (PREMIA) and Lind today announced the formation of Lind Asia, a strategic joint venture dedicated to revolutionizing clinical trial enrollment in the Asia-Pacific region. Lind Asia will serve…...
Tedopi Plus Pembrolizumab Improves Progression-Free Survival in Ovarian Cancer
15+ hour, 24+ min ago (101+ words) The Clinical Trial Vanguard Tedopi Plus Pembrolizumab Improves Progression-Free Survival in Ovarian Cancer A hazard ratio of 0. 53 against best supportive care sounds straightforward until you examine the baseline: median progression-free survival in the control arm was just 2. 8 months, reflecting a…...
Al-Ola A Abdallah Comments On the New Article on Dual-Target CAR-T Strikes Hard in EMD - Onco Daily
19+ hour, 31+ min ago (269+ words) Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on'X: "Dual-Target CAR-T Strikes Hard in EMD: ORR 97%, PFS 6 months! Is Persistence the Missing…...
One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial
19+ hour, 19+ min ago (483+ words) A single infusion of VERVE-102 sharply lowered PCSK9 and LDL cholesterol in a small phase 1 trial, offering early evidence for a potentially durable genetic approach to cholesterol control, while long-term safety and clinical benefit remain to be proven. Study: In Vivo…...
Eli Lilly Gene Therapy Cuts Cholesterol Dramatically in Early Trial
15+ hour, 31+ min ago (63+ words) Whalesbook Eli Lilly's gene-editing therapy VERVE-102 has shown impressive early results, cutting LDL-C by 62% and PCSK9 protein by 88% in a Phase 1b trial. This one-time treatment, acquired from Verve Therapeutics, aims to offer a permanent solution for high cholesterol patients, reducing the…...
Can an injection prevent heart attacks? Eli Lilly's gene-editing therapy cuts LDL cholesterol by 62%
19+ hour, 57+ min ago (279+ words) In an early-stage clinical trial, published in "The New England Journal of Medicine" and presented at the European Atherosclerosis Society Congress this week, researchers reported that a single infusion of a gene-editing therapy called VERVE-102 sharply lowered LDL cholesterol by…...
New Pill May Replace CPAP for People with Sleep Apnea
21+ hour, 54+ min ago (580+ words) ...